Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™

PHASE3CompletedINTERVENTIONAL
Enrollment

256

Participants

Timeline

Start Date

March 20, 2018

Primary Completion Date

August 11, 2022

Study Completion Date

August 11, 2022

Conditions
Diffuse Large B-Cell Lymphoma
Interventions
DRUG

Enzastaurin Hydrochloride

R-CHOP + Enzastaurin (Kinenza®) 125 mg

OTHER

R-CHOP + placebo

R-CHOP + placebo

Trial Locations (39)

10029

Icahn School of Medicine at Mount Sinai, New York

10595

New York Medical College, Hawthorne

11794

Stony Brook Cancer Center, Stony Brook

35805

Oncology Specialties: Clearview Cancer Institute, Huntsville

40241

Norton Cancer Institute Oncology Practices - St. Matthews Location, Louisville

43623

Toledo Clinic Cancer Centers, Toledo

44646

Tri-County Hematology & Oncology Associates, Inc., Massillon

44708

Hematology & Oncology Associates, Inc., Canton

46202

Indiana University, Indianapolis

53215

Vince Lombardi Cancer Center (Aurora St. Luke's Medical Center), Milwaukee

53792

University of Wisconsin Hospital and Clinics, Madison

55905

Mayo Clinic, Rochester, Rochester

60153

Loyola University Medical Center, Maywood

61615

Illinois CancerCare, Peoria

63104

Saint Louis University, St Louis

65806

Mercy Research, Springfield

72205

Central Arkansas Radiation Therapy Institute, Little Rock

75235

University of Texas Southwestern Medical Center - Harold C. Simmons Comprehensive Cancer Center, Dallas

77024

Oncology Consultants: Memorial City, Houston

85719

University of Arizona, Tucson

89169

Comprehensive Cancer Centers of Nevada, Las Vegas

92270

Desert Hematology, Rancho Mirage

98104

Swedish Cancer Institute, Seattle

98109

Seattle Cancer Center Alliance, Seattle

100142

Beijing Cancer Hospital, Beijing

100191

Peking University Third Hospital (Hematology Dept), Beijing

116044

Second Affiliated Hospital of Dalian Medical University, Dalian

130012

JiLin Cancer Hospital(Lymphoma hematology Dept), Changchun

150081

Harbin Medical University Cancer Hospital (Oncology Internal), Harbin

200032

Fudan University Shanghai Cancer Hospital, Shanghai

300060

Tianjin Medical University Cancer Institute and Hospital, Tianjin

310022

ZheJiang Cancer Hospital ( Lymphoma Dept), Hangzhou

450003

HeNan Cancer Hospital (Hematology Dept), Zhengzhou

450052

The First Affiliated Hospital of ZhengZhou University (Oncology Dept), Zhengzhou

510080

GuangDong General Hospital, Guangzhou

637400

West China Hospital of Sichuan University (Hematology Dept), Chengdu

03766

Norris Cotton Cancer Center Dartmouth-Hitchcock Medical Center, Lebanon

07960

Summit Medical Group, Morristown

07972

Atlantic Health System/ Morristown Meeical Center, Morristown

Sponsors
All Listed Sponsors
lead

Denovo Biopharma LLC

INDUSTRY

NCT03263026 - Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™ | Biotech Hunter | Biotech Hunter